Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ceftazidime in clinical practice.

K Alestig, T Eilard, R Norrby

    The Journal of Antimicrobial Chemotherapy
    |July 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Contact allergy to aluminium induced by commonly used pediatric vaccines.

    Clinical and translational medicine·2017
    Same author

    Isolation of L-forms reverting to Staphylococcus aureus from pus of patients with staphylococcal infections: a study on 31 cases of staphylococcal infections treated with antibiotics.

    Scandinavian journal of infectious diseases·2015
    Same author

    The impact of vaccines on public health: the role of ESCMID.

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2014
    Same author

    Outlook for a dengue vaccine.

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2014
    Same author

    The value of selected in vitro and in silico methods to predict acute oral toxicity in a regulatory context: results from the European Project ACuteTox.

    Toxicology in vitro : an international journal published in association with BIBRA·2012
    Same author

    Reported occupational injuries at Swedish recycling centres - based on official statistics.

    Ergonomics·2011
    Same journal

    Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing.

    The Journal of antimicrobial chemotherapy·2026
    Same journal

    A review of the randomized clinical trial results from the Staphylococcus aureus network adaptive platform (SNAP) meticillin-susceptible (MSSA) and penicillin-susceptible (PSSA) domains and CloCeBa.

    The Journal of antimicrobial chemotherapy·2026
    Same journal

    Incidence and factors associated with subtherapeutic cefazolin levels among patients with severe infections.

    The Journal of antimicrobial chemotherapy·2026
    Same journal

    Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections.

    The Journal of antimicrobial chemotherapy·2026
    Same journal

    Microbiology testing around the time of antibiotic initiation among residents of long-term care facilities.

    The Journal of antimicrobial chemotherapy·2026
    Same journal

    Insights into the mechanisms underlying cell wall-active agents and gentamicin bactericidal synergism against Enterococcus faecalis.

    The Journal of antimicrobial chemotherapy·2026
    See all related articles

    Intravenous ceftazidime effectively treated various infections, clearing most pathogens. While generally safe, caution is advised for patients with kidney issues, and adverse effects were noted in some individuals.

    Area of Science:

    • Infectious Diseases
    • Pharmacology
    • Clinical Medicine

    Background:

    • Ceftazidime is a third-generation cephalosporin antibiotic.
    • Bacterial infections pose significant health challenges.
    • Effective antibiotic therapy is crucial for patient outcomes.

    Purpose of the Study:

    • To evaluate the efficacy and safety of intravenous ceftazidime.
    • To assess ceftazidime's impact on common bacterial pathogens.
    • To identify patient populations requiring dosage adjustments.

    Main Methods:

    • Open-label trial involving 106 adult patients.
    • Treatment administered intravenously.
    • Infections included urinary, respiratory, soft tissue, osteitis, and septicaemia.

    Related Experiment Videos

    Main Results:

    • Ceftazidime demonstrated high efficacy, clearing 79% of pre-treatment isolates.
    • Clinical cure was achieved in 70% of patients, with improvement in 25%.
    • Adverse events included renal impairment in three patients and other side effects in 13.

    Conclusions:

    • Intravenous ceftazidime is an effective treatment for various bacterial infections.
    • Dosage modification may be necessary for patients with renal impairment.
    • Ceftazidime exhibits a generally favorable safety profile with manageable side effects.